<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41098">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571361</url>
  </required_header>
  <id_info>
    <org_study_id>SM2-KHT-2015 - v2</org_study_id>
    <secondary_id>2015-002239-16</secondary_id>
    <nct_id>NCT02571361</nct_id>
  </id_info>
  <brief_title>PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial</brief_title>
  <acronym>PANSAID</acronym>
  <official_title>PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel HÃ¤gi-Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Naestved Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial name: PAracetamol and NSAID in combination: A randomised, blinded, parallel, 4-group
      clinical trial

      Trial acronym: PANSAID

      Background: Effective postoperative pain management is essential for the well-being and
      rehabilitation of the surgical patient. No &quot;gold standard&quot; exists after total hip
      arthroplasty (THA) and combinations of different non-opioid medications are used with
      virtually no evidence for additional analgesic efficacy compared to monotherapy.

      Objectives: The objective of this trial is to investigate the analgesic effects and safety
      of paracetamol and ibuprofen and their combination in different dosages after THA.

      Intervention: Patients are randomised to 4 groups: A) paracetamol 1 g x 4 and ibuprofen 400
      mg x 4; B) paracetamol 1 g x 4 and placebo (ibuprofen); C) placebo (paracetamol) and
      ibuprofen 400 mg x 4; and D) paracetamol 0,5 g x 4 and ibuprofen 200 mg.

      Design: Placebo controlled, parallel 4-group, multicentre trial with adequate centralised
      computer-generated allocation sequence and allocation concealment with varying block size
      and stratification by site. Blinding of assessor, investigator, caregivers, patients, and
      statisticians.

      Sample size: 556 eligible patients are needed to detect a difference of 10 mg morphine the
      first postoperative day with a standard deviation of 20 mg and a type 1 error rate of 0,004
      (two-sided) and a type 2 error rate of 0,10.

      We preplan the following sub-studies:

        1. A re-analysis of benefit outcomes (pain and opioid consumption) with respect to the
           following sub-groups: sex, age, ASA-score, type of surgery (uncemented, cemented, or
           hybrid), surgical site (posterior approach vs. anterolateral approach) and anaesthetic
           technique (general anaesthesia vs. spinal anaesthesia)

        2. A re-analysis of harm (adverse events and opioid related side effects) with respect to
           the following groups sex, age, ASA-score anaesthetic technique (general anaesthesia vs.
           spinal anaesthesia) and opioid consumption (in the intervention period).

        3. Longer follow-up than the specified 90 days (1 year)

        4. An analysis of the association between VAS-scores and opioid consumption

        5. Time-to-event analyses regarding use of PCA-morphine

        6. An analysis of the association between preoperative analgesic use and pain/morphine
           consumption

        7. An analysis of the individual patients: how many will achieve &quot;no worse than mild pain&quot;
           (NRS&lt;3) More sub-studies may be performed post-hoc and they will be clearly identified
           as such.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption the first 24 hours postoperatively</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Total need for morphine administered as BOTH patient controlled analgesia (PCA) for the first 24 hours postoperatively AND supplemental morphine administered at the post-anaesthesia unit the first hour postoperatively. Bolus 2.0 mg; lockout: 10 min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>0-90 days postoperatively</time_frame>
    <description>Serious adverse events, including death, within 90 days after surgery defined as SAE (according to ICH-GCP-guidelines) except &quot;prolongation of hospitalisation&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain during movement at 6 hours postoperatively (visual analogue scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Pain scores (visual analogue scale (VAS)) with active 30 degrees flexion of the hip at 6 hours postoperatively. No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain during movement at 24 hours postoperatively (visual analogue scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Pain scores (visual analogue scale (VAS)) with active 30 degrees flexion of the hip at 24 hours postoperatively. No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest at 6 hours postoperatively (visual analogue scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Pain scores (visual analogue scale (VAS)) at rest at 6 hours postoperatively. No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest at 24 hours postoperatively (visual analogue scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Pain scores (visual analogue scale (VAS)) at rest at 24 hours postoperatively. No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Number of patients with one or more adverse events in the intervention period (0-24 hours)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Nausea at 6 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Level of nausea at 6 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Nausea at 24 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Level of nausea at 24 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Vomiting the first 24 hours postoperatively</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Number of vomiting episodes (0-24 hours) measured in the periods 0-6 and 6-24 hours postoperatively</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-emetic treatment the first 24 hours postoperatively</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Consumption of ondansetron in the period 0-24 hours postoperatively</description>
  </other_outcome>
  <other_outcome>
    <measure>Sedation at 6 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Level of sedation at 6 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Sedation at 24 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Level of sedation at 24 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood loss intraoperatively</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Blood loss during the surgical procedure (intraoperatively)</description>
  </other_outcome>
  <other_outcome>
    <measure>Days alive and outside hospital within 90 days after surgery.</measure>
    <time_frame>0-90 days postoperatively</time_frame>
    <description>Days alive and outside hospital within 90 days after surgery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Dizziness at 6 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Level of dizziness at 6 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Dizziness at 24 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Level of dizziness at 24 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">556</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Treatment A:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paracetamol 1g + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paracetamol 1g + placebo orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paracetamol 0,5 g + ibuprofen 200 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol (1g x 4)</intervention_name>
    <description>Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively</description>
    <arm_group_label>Treatment A:</arm_group_label>
    <arm_group_label>Treatment B:</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen (400 mg x 4)</intervention_name>
    <description>Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively</description>
    <arm_group_label>Treatment A:</arm_group_label>
    <arm_group_label>Treatment C:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol (0,5 g x 4)</intervention_name>
    <description>Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively</description>
    <arm_group_label>Treatment D:</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen (200 mg x 4)</intervention_name>
    <description>Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively</description>
    <arm_group_label>Treatment D:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (x4)</intervention_name>
    <description>Given in 6 hour intervals the first 24 hours postoperatively</description>
    <arm_group_label>Treatment B:</arm_group_label>
    <arm_group_label>Treatment C:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for unilateral, primary Total Hip Arthroplasty (THA)

          -  Age &gt; 18

          -  ASA 1-3.

          -  BMI &gt; 18 and &lt; 40

          -  Women in the fertile age must have negative urine HCG pregnancy test

          -  Patients who gave their written informed consent to participating in the trial after
             having fully understood the contents of the protocol and restrictions.

        Exclusion Criteria:

          -  Patients who cannot cooperate with the trial.

          -  Concomitant participation in another trial

          -  Patients who cannot understand or speak Danish.

          -  Daily use of strong opioids (tramadol and codein are accepted)

          -  Patients with allergy to the medicines used in the trial.

          -  Contraindications against NSAID, for example previous ulcer, heart failure, liver
             failure, or renal failure (eGRF &lt; 60 ml/kg/1,73m2), known thrombocytopenia (&lt;100
             mia/L)

          -  Patients suffering from alcohol and/or drug abuse - based on the investigator's
             judgement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel HÃ¤gi-Pedersen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, NÃ¦stved Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kasper H Thybo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology, NÃ¦stved Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ole Mathiesen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, KÃ¸ge Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JÃ¸rgen B Dahl, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JÃ¸rn Wetterslev, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Copenhagen Trial Unit, Center for Clinical Intervention Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Pohlman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, NykÃ¸bing Falster Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Henrik BÃ¼low, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, HolbÃ¦k Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel HÃ¤gi-Pedersen, MD, PhD</last_name>
    <phone>+4556514792</phone>
    <email>dhag@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kasper H Thybo, MD</last_name>
    <phone>+4556514793</phone>
    <email>khty@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GildhÃ¸j Privathospital</name>
      <address>
        <city>KÃ¸benhavn</city>
        <state>BrÃ¸ndby</state>
        <zip>2605</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Anker Pedersen, MD</last_name>
      <email>nap@gildhoj.dk</email>
    </contact>
    <investigator>
      <last_name>Niels Anker Pedersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HolbÃ¦k Hospital</name>
      <address>
        <city>HolbÃ¦k</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Poul Erik Svendsen, MD</last_name>
      <email>poes@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Poul Erik Svendsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KÃ¸ge Hospital</name>
      <address>
        <city>KÃ¸ge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Matiesen, MD, PhD</last_name>
      <email>omat@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Ole Matiesen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NykÃ¸bing Falster Hospital</name>
      <address>
        <city>NykÃ¸bing Falster</city>
        <zip>4800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamilla Skovmand, MD</last_name>
      <email>kne@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Kamilla Skovmand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan G BjÃ¸rck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NÃ¦stved Hospital</name>
      <address>
        <city>NÃ¦stved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel HÃ¤gi-Pedersen, MD, PhD</last_name>
      <phone>+45 56514792</phone>
      <email>dhag@regionsjaelland.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kasper H Thybo, MD</last_name>
      <phone>+45 56514793</phone>
      <email>khty@regionsjaelland.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Kasper H Thybo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrik SchrÃ¸der, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harald Schmidt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital (OUH)</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SÃ¸ren Overgaard, MD, DMsc</last_name>
      <phone>+45 59484105</phone>
      <email>soeren.overgaard@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Annie Gam</last_name>
      <phone>23464201</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 16, 2017</lastchanged_date>
  <firstreceived_date>October 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Naestved Hospital</investigator_affiliation>
    <investigator_full_name>Daniel HÃ¤gi-Pedersen</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Acetaminophen</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Arthroplasty, Replacement, Hip</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
